- Conditions
- Bacterial Infection, Multiple-drug Resistance, Pathogen Resistance
- Interventions
- Fosfomycin disodium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 9,939
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- Ditiocarb sodium
- Drug
- Lead sponsor
- Merieux Institute
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 5 more
- Conditions
- HIV Infections
- Interventions
- MPER-656 Liposome Vaccine, Placebo for MPER-656 Liposome Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Cytomegalovirus Infections, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 13 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- San Francisco, California • Washington D.C., District of Columbia
- Conditions
- HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
- Interventions
- Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)
- Behavioral
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Colbert, Georgia
- Conditions
- Vaginal Laceration During Delivery
- Interventions
- Augmentin/Flagyl or Augmentin/Clindamycin, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- E Coli Infection
- Interventions
- no Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Rheumatoid Arthritis, Chronic Hepatitis B
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections, Adherence, Medication
- Interventions
- Tech2Check
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Baltimore, Maryland
- Conditions
- Hepatitis C Virus
- Interventions
- SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lung Cancer, Lung Infection, Breast Cancer, Malignant Pleural Effusion, Empyema
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HIV Infections
- Interventions
- HIV gp120/NefTat/AS02A Vaccine
- Biological
- Lead sponsor
- Marcus Altfeld, M.D., Ph.D.
- Individual
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Bone Marrow Transplant Infection
- Interventions
- Not listed
- Lead sponsor
- Karius, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections, Hepatitis C
- Interventions
- Ribavirin, Aldesleukin, Peginterferon alfa-2b
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Dolutegravir Sodium Monohydrate, Ibalizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Trauma, Hiv, Aging
- Interventions
- CoSHA (Coping with childhood Sexual Abuse, HIV, and Aging), Control
- Behavioral
- Lead sponsor
- University of South Carolina
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Columbia, South Carolina
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Surgical Procedure, Unspecified
- Interventions
- Prevena Incision Management System
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Sepsis, Infection
- Interventions
- Up-front individualized dosing algorithm, Usual Care
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- 18F-αvβ6-BP
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Alcohol Use Disorder, Hiv
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Coronavirus Infection
- Interventions
- No intervention
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts